Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Jan 1;20(1):380-2. doi: 10.1016/j.bmcl.2009.10.073. Epub 2009 Oct 28.

Discovery of orally available integrin alpha5beta1 antagonists.

Author information

1
Jerini AG, Invalidenstrasse 130, Berlin D-10115, Germany.

Abstract

Previous research within our laboratories identified the 3-hydroxypyrrolidine scaffold 1 as a new and selective integrin alpha5beta1 inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin alpha5beta1 inhibitor scaffolds for potential systemic treatment is described.

PMID:
19910191
DOI:
10.1016/j.bmcl.2009.10.073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center